Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer
ACS Nano Medicine · 2026-11-12
DOI: 10.1021/acsnanomed.6c00154 ↗Abstract
Abstract Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.
EUVIMED